Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Currently, concurrent chemoradiotherapy with/without sequential chemotherapy is the standard
treatment modality for intermediate risk NPC (stage II and T3N0M0) according to the National
Comprehensive Cancer Network guideline. However these recommendations were based on the
evidence in the two-dimensional conventional radiotherapy (2DCRT) era. The introduction of
intensity-modulated radiotherapy (IMRT) in NPC treatment has brought substantial better
treatment outcomes than 2DCRT. It has been questioned whether additional concurrent
chemotherapy is still necessary for intermediate risk NPC within the excellent framework of
IMRT. Thus, the investigators jointly conduct the first non-inferior randomized trial to
determine the value of concurrent chemotherapy with cisplatin for intermediate risk NPC
patients treated with IMRT. Given the results of clinical studies mentioned above,the
investigators decide to adopt the concurrent regimen to be cisplatin 100 mg/m2 on day 1, 22,
43
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Fifth Affiliated Hospital, Sun Yat-Sen University First People's Hospital of Foshan Guilin Medical University, China